



image

\$ 1655
Patent 1635

Attorney's Docket No. 017753-154

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Thérèse de BIZEMONT *et al.*) Group Art Unit: 1635/
Application No.: 09/836,439) Examiner: Richard A. Schnizer
Filed: April 17, 2001) Confirmation No.: 5851
For: GENE THERAPY WITH CHIMERIC)
OLIGONUCLEOTIDES DELIVERED)
BY A METHOD COMPRISING A STEP)
OF IONTOPHRESIS)

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c) the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

A fee in the amount of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is enclosed.

To assist the Examiner, the document are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

10/31/2003 KBETEM1 00000002 09836439

01 FC:1806


180.00 DP

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: October 30, 2003

By:


Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

1635
3



Patent
Attorney's Docket No. 017753-154

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Thérèse de BIZEMONT <i>et al.</i>)	Group Art Unit: 1635
Application No.: 09/836,439)	Examiner: Richard A. Schnizer
Filed: April 17, 2001)	Confirmation No.: 5851
For: GENE THERAPY WITH CHIMERIC)	
OLIGONUCLEOTIDES DELIVERED)	
BY A METHOD COMPRISING A STEP)	
OF IONTOPHRESIS)	

INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.


- ☐ No additional fee for submission of an IDS is required.
- ☒ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☒ A check in the amount of \$ 180.00 is enclosed for the fee due.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: October 30, 2003

By: 
Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Substitute for forms 1449A/PTO & 1449B/PTO

ATTORNEY'S DKT NO.
017753-154APPLICATION NO.
09/836,439SECOND INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Thérèse de BIZEMONT *et al.*FILING DATE
April 17, 2001GROUP
1635

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	5,760,012		Eric B. KMIEC <i>et al.</i>	06-02-1998
	6,154,671		Jean-Marie PAREL <i>et al.</i>	11-28-2000

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	(Abstract only) STODULKOVA <i>et al.</i> , "Initial Test of Chimeraplasty in Correcting a Mouse Retinal Degeneration" IOVS, 2001, pg. S346, Vol. 42, No. 4, Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, USA, April 29 - May 4, 2001
	(Abstract only) DE BIZEMONT <i>et al.</i> , "Confocale Laser Scanning Microscopy of the Anterior Segment of the Rat and Mouse Eye after Iontophoresis of Fluorescent Antisense Oligonucleotides", IOVS, 2001, pg. S171, Vol. 42, No. 4, Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, USA, April 29-May 4, 2001
	ASAHARA <i>et al.</i> , "Induction of Gene into the Rabbit Eye by Iontophoresis: Preliminary Report", Japanese Journal of Ophthalmology, 2001, pgs. 31-39, Vol. 45, Japanese Ophthalmological Society, Elsevier Science, Inc., Oxford, ENGLAND
	SOHOCKI <i>et al.</i> , "Prevalence of Mutations Causing Retinitis Pigmentosa And Other Inherited Retinopathies", Human Mutation, 2001, pgs. 42-51, Vol. 17, No. 1, Wiley-Liss, Inc., New York, New York, USA
	OZAKI <i>et al.</i> , "Hypoxia Inducible Factor-1alpha Is Increased in Ischemic Retina: Temporal and Spatial Correlation with VEGF Expression", Investigative Ophthalmology and Visual Science, 1999, pgs. 182-189, Vol. 40, No. 1, Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, USA
	PRÉAT <i>et al.</i> , "Topical Delivery of Nucleic Acids in the Skin", S.T.P. Pharma Sciences, 2000, pgs. 57068, Vol. 11, No. 1, Societe Française des Sciences et Techniques Pharmaceutiques, Paris, France
	KMIEC <i>et al.</i> , "Targeted Gene Repair in Mammalian Cells Using Chimeric Oligonucleotides", Genetic Engineering, 2000, pgs. 23-31, Vol. 22, Plenum Press, New York, New York, USA
	ALEXEEV <i>et al.</i> , "Localized in Vivo Genotypic and Phenotypic Correction of the Albino Mutation in Skin by RNA-DNA Oligonucleotide", Nature Biotechnology, 2000, pgs. 43-47, Vol. 18, No. 1, Nature America, New York, New York, USA
	KMIEC <i>et al.</i> , "Targeted Gene Repair - in the Arena", The Journal of Clinical Investigation, 2003, pgs. 632-636, Vol. 112, No. 5, American Society for Clinical Investigation, Thorofare, New Jersey, USA
	(Abstract only) BERDUGO <i>et al.</i> , "Delivery of Antisense Oligonucleotide to the Cornea by Iontophoresis", Antisense Nucleic Acid Drug Dev., 2003, pgs 107-114, Vol. 13, No. 2, Ipswich, Massachusetts, USA
	(Abstract only) KURZ <i>et al.</i> , "Novel Approaches for Retinal Drug Delivery", Ophthalmol Clin North Am., 2002, pgs. 405-10, Vol. 15, No. 3, W.B. Saunders Co., Philadelphia, Pennsylvania, USA
	VOIGHT <i>et al.</i> , "Down-regulation of NOSII Gene Expression by Iontophoresis of Anti-sense Oligonucleotide in Endotoxin-induced Uveitis", Biochemical and Biophysical Research Communications, 2002, pgs. 336-341, Academic Press, London, England
	(Abstract only) KEEN <i>et al.</i> , "Autosomal Dominant Retinitis Pigmentosa: Four New Mutations in Rhodopsin, One of Them in the Retinal Attachment Site", Genomics, 1991, pgs. 199-205, Vol. 11, No. 1, Academic Press, San Diego, California
	(Abstract only) ROBINSON <i>et al.</i> , "Constitutively Active Mutants of Rhodopsin", Neuron, 1992, pgs. 719-25, Vol. 9, No. 4, Cell Press, Cambridge, Massachusetts, USA
	LIANG <i>et al.</i> , "Optimizing the Delivery Systems of Chimeric RNA-DNA Oligonucleotides. Beyond General Oligonucleotide Transfer", Eur. J. Biochem, 2002, pgs. 5753-5758, Vol. 269, Blackwell Science, Berlin, Germany
	ROBINSON <i>et al.</i> , "Opsins with Mutations at the Site of Chromophore Attachment Constitutively Activate Transducin but Are Not Phosphorylated by Rhodopsin Kinase", Proc. Natl. Acad. Sci USA, 1994, pgs. 5411-5415, Vol. 91, National Academy of Sciences, Washington, D.C., USA
	International Search Report for corresponding International Application No. PCT/IB02/02310, dated April 14, 2003

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.